ELITE PHARMS INC - ELTP STOCK NEWS

Elite Pharmaceuticals (OTCQB: ELTP) has received FDA approval for its generic version of Vyvanse (Lisdexamfetamine Dimesylate) capsules in seven different strengths ranging from 10 mg to 70 mg. The medication is designed to treat Attention Deficit Hyperactivity Disorder (ADHD). According to IQVIA data, the combined brand and generic market for this product recorded annual sales of $4.3 billion for the twelve months ending September 2024.

Elite Pharmaceuticals (OTCQB: ELTP) reported strong financial results for Q2 FY2025 ended September 30, 2024. Consolidated revenues reached $18.9 million, marking a significant 33% increase ($4.7 million) compared to the same period last year. Operating profits rose to $3.5 million, showing an impressive 84% growth ($1.6 million) year-over-year. The improved performance was primarily driven by higher sales in Elite's label product line during the quarter.

Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company, announced it will release its second quarter financial results for fiscal year 2025 on November 14, 2024. A live conference call to discuss these results and provide a business update is scheduled for November 15, 2024, at 11:30 AM EST. Stockholders can submit questions to be addressed during the call, with general queries due by November 13 and financial questions by November 14. The call will be accessible via dial-in numbers and an audio replay will be available on the company's website.

Elite Pharmaceuticals (OTCQB: ELTP) has received approval from the Israeli Ministry of Health for its generic version of Adderall®. The product, an immediate-release mixed salt of amphetamine, will be available in 10 mg, 20 mg, and 30 mg tablets. Elite will supply the product to Dexcel Pharma, its exclusive distributor for the Israeli market.

The generic Adderall® is indicated for treating Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. Under the agreement, Elite will manufacture and package the product under Dexcel's label, while Dexcel will handle sales, marketing, and distribution. Dexcel will pay an agreed transfer price and share profits under certain conditions. The product is jointly owned by Elite and Mikah Pharma .

The first shipment timeline depends on licensee orders, DEA quotas, and manufacturing processes, which could take months to complete.

Elite Pharmaceuticals (OTCQB: ELTP) has announced the commercial launch of its generic version of Tylenol with Codeine (acetaminophen and codeine phosphate) tablets. The product is available in three strengths: 300mg/15mg, 300mg/30mg, and 300mg/60mg. These tablets are indicated for managing mild to moderate pain where opioid treatment is appropriate and alternative treatments are inadequate.

The product is marketed and sold under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of acetaminophen and codeine in these strengths were approximately $47 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment for pain management medications.

Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic methotrexate sodium 2.5 mg tablets. This medication is a dihydrofolate reductase inhibitor used to treat various conditions in adults and children, including acute lymphoblastic leukemia, rheumatoid arthritis, and severe psoriasis.

The product is marketed under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of methotrexate sodium 2.5 mg tablets were approximately $63 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment within the pharmaceutical industry.

Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q1 FY2025 ended June 30, 2024. Highlights include:

- Consolidated revenues of $18.8 million, up 109% year-over-year
- Operating profits of $3.9 million, increased 144% year-over-year
- Net income attributable to common shareholders of $0.6 million

The significant growth in operating profits was primarily due to higher sales of Elite label products. The company will host a conference call on August 15, 2024, at 11:30 AM EDT to discuss the results and provide business updates. Stockholders can submit questions in advance to dianne@elitepharma.com by August 14, 2024, 7:00 PM EDT.

Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, has announced its upcoming financial release and conference call schedule. The company will release its first quarter financial results for fiscal year 2025 on August 14, 2024. Following this, Elite's management will host a live conference call on August 15, 2024, at 11:30 AM EDT to discuss the financial and operating results, as well as provide a general business update.

Stockholders are encouraged to submit questions to the company prior to the call. The dial-in numbers for the conference are 1-800-346-7359 (domestic) and 1-973-528-0008 (international), with the conference number 98840. An audio replay will be available on the company's website.

Elite Pharmaceuticals announced its fiscal year-end results for March 31, 2024, showing a significant performance boost. The company reported consolidated revenues of $56.6 million, marking a 65% increase from the previous fiscal year. Operating profits surged by 192% to $10.8 million, largely due to the launch of the Elite label product line. Net income attributable to common shareholders stood at $20.1 million. Elite will host a conference call on July 2, 2024, at 11:30 AM EDT to discuss these results and recent business developments. Stockholders are encouraged to submit financial questions in advance.